Synthesis and in vitro anti-tumor activity of N-{1-[(3-thioxo-5,6-dihydroimidazo[2,1-c][1,2,4]thiadiazol-7-ylthio)thiocarbonyl]-2-imidazolidene}arylsulfonamides

Bioorganic and Medicinal Chemistry Letters

Volumn 16, Issue 14, 2006, Pages 3663-3667

  Saczewski, Jarosław ^a   Brzozowski, Zdziaław ^a   Saczewski, Franciszek ^a   Bednarski, Patrick J ^b   Liebeke, Manuel ^b   Gdaniec, Maria ^c  

^a MEDICAL UNIVERSITY OF GDANSK   (Poland)

^b UNIVERSITY OF GREIFSWALD   (Germany)

^c ADAM MICKIEWICZ UNIVERSITY   (Poland)

Author keywords

Anti tumor activity; Sulfenamides; Sulfonamides; Synthesis

Indexed keywords

ANTINEOPLASTIC AGENT; BENZENE DERIVATIVE; IMIDAZOLE DERIVATIVE; SULFONAMIDE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CHEMICAL REACTION; CONTROLLED STUDY; DRUG ACTIVITY; DRUG SELECTIVITY; DRUG SYNTHESIS; HUMAN; HUMAN CELL; IN VITRO STUDY; LEUKEMIA CELL LINE; STRUCTURE ACTIVITY RELATION;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; HUMANS; INHIBITORY CONCENTRATION 50; LEUKEMIA, LYMPHOCYTIC; STRUCTURE-ACTIVITY RELATIONSHIP; SULFONAMIDES; THIADIAZOLES;

EID: 33746507903     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2006.04.067     Document Type: Article

References (29)

1. van den Nieuwendijk A.M.C.H., Pietra D., Heltman L., Goblyos A., and IJzerman A.P. J. Med. Chem. 47 (2004) 663
2. Goblyos A., de Vries H., Brussee J., and IJzerman A.P. J. Med. Chem. 48 (2005) 1145
3. Jung K.-Y., Kim S.-Y., Gao Z.-G., Gross A.S., Melman N., Jacobsen K.A., and Kim Y.-Ch. Bioorg. Med. Chem. 12 (2004) 613
4. Pan K., Scott M.K., Lee D.H.S., Fitzpatrick L.J., Crooke J.J., Rivero R.A., Rosenthal D.I., Vaidya A.H., ZXhao B., and Reitz A.B. Bioorg. Med. Chem. 11 (2003) 185
5. Martinez A., Castro A., Cardelus I., Llenas J., and Palacios J.M. Bioorg. Med. Chem. 5 (1997) 1275
6. Song Y., Connor D.T., Sercel A.D., Sorenson R.J., Doubleday R., Unangst P.C., Roth B.D., Beylin V.C., Gilbertson R.B., Chan K., Schrier D.J., Guglietta A., Bornemeier D.A., and Dyer R.D. J. Med. Chem. 42 (1999) 1161
7. Bongartz J.-P., Stokbroekx R., Van der Aa M., Luyckx M., Willems M., Ceusters M., Meerpoel L., Smets G., Jansen T., Wouters W., Bowden C., Valletta L., Herb M., Tominovich R., and Tuman R. Bioorg. Med. Chem. Lett. 12 (2002) 589
8. Yoshizawa H., Kubota T., Itani H., Ishitobi H., Miwa H., and Nishitani Y. Bioorg. Med. Chem. 12 (2004) 4211
9. Piskala A., Vachalkova A., Masojidkova M., Horvathova K., Olesna Z., Paces V., and Nowotny L. Pharmazie 59 (2004) 756
10. Martinez A., Alonso M., Castro A., Perez C., and Morena F.J. J. Med. Chem. 45 (2002) 1292
11. Martinez A., Fernandez E., Castro A., Conode S., Rodriguez-Franco I., Banos J.-E., and Badia A. Eur. J. Med. Chem. 35 (2000) 913
12. Marrano C., de Macedo P., Gagnon P., Lapierre D., Gravel C., and Keillor J.W. Bioorg. Med. Chem. 9 (2001) 3231
13. Karimian, K.; Tam, T. F.; Desilets, D.; Lee, S.; Cappeltto, T.; Li, W. Apotex Research Inc., U.S. Patent 1997, 5, 677, 302, October 14.
14. Leung-Toung R., Wodzinska J., Li W., Lowrie J., Kukreja R., Desilets D., Karimian K., and Tam T.F. Bioorg. Med. Chem. 11 (2003) 5529
15. Almajan G.L., Innoccenti A., Puccetti L., Manole G., Barbuceanu S., Saramet I., Scozzafava A., and Supuran C.T. Bioorg. Med. Chem. Lett. 15 (2005) 2347
16. Winum J.-Y., Innoccenti A., Nasr J., Montero J.-L., Scozzafava A., Vullo D., and Supuran C.T. Bioorg, Med. Chem. Lett. 15 (2005) 2353
17. Puccetti L., Fasolis G., Cecchi A., Winum J.-Y., Gamberi A., Montero J.-L., Scozzafava A., and Supuran C.T. Bioorg. Med. Chem. Lett. 15 (2005) 2359
18. Scozzafava A., Owa T., Mastrolorenzo A., and Supuran C.T. Curr. Med. Chem. 10 (2003) 925
19. Pastorekova S., Parkkila S., Pastorek J., and Supuran C.T. J. Enzyme Inhib. Med. Chem. 19 (2004) 199
20. Gaspari P., Banerjee T., Malachowski W.P., Muller A.J., Prendergast G.C., DuHadway J., Bennett S., and Donovan A.M. J. Med. Chem. 49 (2006) 684
21. Saczewski F., Saczewski J., and Gdaniec M. J. Org. Chem. 68 (2003) 4791
22. General procedure for the synthesis ofN-{1-[(3-thioxo-5,6-dihydroimidazo[2,1-c][1,2,4]thiadiazol-7-lythio)-thiocarbonyl]2-imidazolidene}arylsulfonamides (2a-z). 6,7-Dihydro-5H-imidazo[2,1-c][1,2,4]thiadiazole-3-thione (1) (0.5 g, 3.14 mmol) was dissolved in pyridine (10 mL). The resulting solution was cooled to 0 °C and a corresponding sulfonyl chloride (1.89 mmol) was added. The reaction mixture was stirred for 12 h at room temperature. Then, water was added (15 mL) and the solution was concentrated under reduced pressure to half of its initial volume. The oily product 2 thus obtained was purified by either crystallization or column chromatography (see Supplementary material).
23. Benati L., Montevecchi P.C., and Spagnolo P. Tetrahedron 49 (1993) 5365
24. 50 = molar concentration of the compound leading to 50% net cell death). Furthermore, a mean graph midpoint (MG_MID) is calculated for each of the mentioned parameters, giving an averaged activity parameter over cell lines. Selectivity of a compound with respect to one or more cell lines of the screen is characterized by a high deviation of the particular cell line parameter compared to the MG_MID value.
25. Boyd M.R. Am. Assoc. Cancer Res. 30 (1989) 652
26. Monks A., Scudiero D., Skehan P., Shoemaker R., Poull K., Vistica D., Hose C., Langley J., Cronise P., Vaigro-Wolf A., Gray-Goodrich M., Cambell H., Mayo J., and Boyd M. J. Natl. Cancer Inst. 83 (1991) 757
27. Weinsten J.N., Myers T.C., O'Connor P.M., Friend S.H., Fornance Jr. A.J., Kohn K.W., Fojo T., Bates S.E., Rubinstein L.V., Anderson N.L., Buolamwini J.K., van Osdol W.W., Monks A.P., Scudiero D.A., Sansiville E.A., Zaharewitz D.W., Bunow B., Viswanadhan V.N., Johnson G.S., Wittes R.E., and Paull K.D. Science 275 (1997) 343
28. Bracht K., Boubakari, Grünert R., and Bednarski P.J. Anticancer Drugs 17 (2006) 41
29. Saczewski J., Frontera A., Gdaniec M., Brzozowski Z., Saczewski F., Tabin P., Quinonero D., and Deya P.M. Chem. Phys. Lett. 422 (2006) 234